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ABSTRACT
Background: Cryptococcal meningitis (CM) is an increasingly prevalent infection 
among HIV/AIDS patients and is becoming a leading cause of morbidity and mortality 
in Africa. The short-term prognosis and management of patients with CM may be 
improved by identifying factors leading to mortality in patients with CM.
Objective: To assess the clinical management and mortality associated with cryptococcal 
meningitis (CM) in patients with acquired immunodeficiency syndrome (AIDS) in 
Kenya.
Design: A retrospective study.
Setting: Kenyatta National Hospital and Mbagathi District Hospital, between August 
2008 and March 2009.
Subjects: Seventy six HIV-infected patients confirmed to be CM positive.
Results: Results show that 30 (40%) of 76 patients diagnosed with CM died during 
hospitalisation after a median hospital stay of ten days (range, 2-73 days). Significant 
predictors of mortality in the univariate model were Mycobacterium tuberculosis 
(TB) co-infection (P = 0.04), having been diagnosed with a co-morbid condition such 
as diabetes mellitus, oral candidiasis and hypertension (P = 0.01), and a low median 
CD4+ T lymphocyte count (P < 0.001). The multivariable model revealed that male sex, 
previous or current anti-retroviral therapy (ART) at admission and CD4+ T lymphocyte 
count less than 50 were significant predictors of mortality. Conversely, a minimum of 
two weeks of amphotericin B treatment (P < 0.001), initiation of ART (P = 0.007) and 
monitoring of creatinine and electrolyte levels (P = 0.02) were significantly associated 
with survival in the univariate model.
Conclusions: CM-associated mortality in Kenya is high; there is an opportunity to 
improve the management and the short-term outcomes of hospitalised HIV positive 
patients with CM in Kenya.
INTRODUCTION
Immunosuppressed individuals are particularly 
susceptible to Cryptococcus neoformans infection and
development of cryptococcal meningitis (CM) (1). In 
regions of the world that are heavily burdened by 
the acquired immunodeficiency syndrome (AIDS) 
epidemic, the incidence rate of AIDS-associated CM is
remarkably high (2). An estimated 720,000 individuals
are infected with CM each year in sub-Saharan Africa
(2).The short-term prognosis of patients with CM is
poor, and the disease is becoming a leading cause of
morbidity and mortality among AIDS patients (3-4).
Even with the most effective treatment, mortality 
typically occurs at a proportion of 9-70% within 3 
months of diagnosis, and in-hospital mortality in 
sub-Saharan Africa occurs at a rate of 25% (2-5).
 This study focused on assessing the management 
of patients with CM in Kenya, where 1.4 million 
people were living with human immunodeficiency 
4 East African Medical Journal July 2014 virus (HIV) 
infection in 2008, the national prevalence of HIV was 
estimated at 7.8% for adults aged 15-49 years and the 
CM-associated mortality was high (2-6).
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The overall prevalence of HIV (approximately 1.2 
million adults aged 15-64 years) in this population 
has decreased nationally to 5.6% in 2012 (6). Current
guidelines for sub-Saharan Africa recommend 1 
mg/ kg/d amphotericin B (AmB) for two weeks 
as induction therapy or, if unavailable, fluconazole 
(FLC) 800 mg for four weeks (7). This is followed by 
fluconazole (FLC) 400 mg/d alone for eight weeks 
and 200 mg/d thereafter for life. Since antifungal 
medication is limited in these regions, other predictors 
of mortality must be identified to ease the burden 
of CM.
 Most studies in Africa that evaluated antifungal
therapy for CM were carried out in South Africa or 
Uganda (8). Considering that treatment for CM is 
similar throughout sub-Saharan Africa, we expected
the clinical outcomes in Kenya to be comparable 
to those found in previous studies. This study was 
conducted to elucidate factors associated with 
mortality in CM in patients with HIV at two public
hospitals in Nairobi, Kenya. Given the limited 
resources in developing areas, the identification of 
modifiable factors associated with mortality will be
helpful in improving in-hospital CM management.
MATERIALS AND METHODS
Study design: A retrospective review of 76 patient 
medical records who were admitted to Kenyatta 
National Hospital (KNH) or Mbagathi District 
Hospital (MDH) between August 2008 and March 
2009 was conducted. Patients considered for this 
study had to be HIV and CM positive. CM diagnosis
had to be confirmed by India ink staining and/or 
cryptococcal antigen testing.
Study settings and participants: KNH is the oldest and
largest referral and teaching hospital in Kenya with
a 1,800 bed capacity. It serves as the primary hospital
for the four million residents in the capital city, 
Nairobi. MDH is a 169-bed public hospital that serves 
as the tuberculosis referral centre for Nairobi. Study
participants included HIV positive patients aged 13
years and older admitted at the two hospitals with a
diagnosis of CM. Ethical approval and permission for
this study was obtained from the University of 
Alabama at Birmingham Institutional Review Board 
(IRB) and the Kenyatta National Hospital Ethics and 
Research Committee.
Patient data collection: A data abstraction sheet was 
used to collect data from each patient’s medical 
records. Variables abstracted included demographic 
characteristics, duration of illness, previous use of 
antifungal drugs, CM treatment, general questions on 
CM management (e.g. rehydration and supplementing 
of potassium chloride, therapeutic lumbar puncture 
(LP), fundoscopy, computed tomography (CT) scan, 
biochemical tests for creatinine, potassium, and blood 
glucose, haemoglobin and use of anaelgesics) and 
clinical status of HIV infection. Date of HIV diagnosis, 
CD4 cell counts, HIV viral load, co-morbidities 
(neurological disorders, chronic conditions and 
microbial infections), discharge status (alive or dead) 
and treatments were also obtained from patient 
records.
Statistical analysis: Categorical variables are presented 
as frequencies and percentages, and continuous 
variables as means and medians. Clinical presentation
and outcome were compared using χ2 test and Fisher’s 
exact test for categorical variables, and student t test 
and z test for continuous variables. Correlation 
analyses were performed to detect multicollinearity 
between independent variables. Multivariable logistic 
regression analyses using a significance level of <0.05 
was used to determine factors associated with CM 
outcomes. Variables that were statistically significant 
at p<0.05 on the bivariate model and those known to
be associated with clinical outcomes of CM based on
previous studies were entered into the multivariable
model using the backward stepwise method. Odds
ratios (OR) and 95% confidence intervals (CI) were
generated as measures of association for all variables
entered into the model. Data analysis was conducted
using SAS, version 9.1 (SAS Institute Inc., Cary, North
Carolina, USA).
RESULTS
Patient characteristics: Characteristics of the patient
cohort are summarised in Table 1. Of the 76 patients
diagnosed with CM, 36 (47%) were seen at KNH and
40 (53%) at MDH. All patients were confirmed to be
HIV positive. Median age of the patients was 35 years
and 61% were males. TB co-infection was reported
in approximately one-third (33%) of the patients. At
the time of admission for CM, 26 patients (34%) were
known to be infected with HIV, and 19 (25%) were
currently or previously on ART. The remaining 50
(66%) patients were diagnosed with HIV while being 
treated in the wards. The median CD4+ T lymphocyte 
count of the patients with CM patients was 31 (Range: 
1- 468) cells/mm3. In addition to CM, other AIDS-
defining illnesses diagnosed in the cohort included 
tuberculosis (33%), Kaposi’s sarcoma (1 patient), and 
candidiasis (1 patient).
Treatment profiles: As indicated in Table 1, 51% of the
patients with CM received and completed the WHO
recommended AmB and FLC combination therapy.
More than 90% of the patients with CM received some
form of antifungal therapy (i.e. combination AmB and
FLC, AmB alone, or FLC alone) and antibiotics for
July 2014 East African Medical Journal 5 treatment 
of CM and bacterial infections other than TB 
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respectively. Most patients received co-trimoxazole 
and/or benzylpenicillin to treat and prevent bacterial 
infections. The majority (79%) of the patients also 
received at least one anaelgesic, the most common of
which was paracetamol (53%).
In-hospital Mortality Profile: A comparison of the short-
term outcome of inpatients is given in Table 2. Overall,
39% (30/76) of the patients confirmed to have CM 
died, with a median time to death of ten days after 
admission. The two-week mortality was 29% (22/76).
Univariate analysis revealed that mortality was 
associated with concomitant TB infection (P=0.04), 
having a co-morbid condition such as diabetes 
mellitus, oral candidiasis and hypertension (p=0.01),
and measuring baseline creatinine and electrolyte 
once (P<0.001). Patients who died had significantly
lower CD4+ T lymphocyte counts compared with 
those who survived (P<0.001). All but two patients 
discharged alive at KNH had their creatinine and 
electrolyte levels measured more than once. Of the 
ten patients who had creatinine and electrolyte levels
measured only once, the six who received AmB all died
(data not shown). A multivariate analysis showed 
that male sex (OR= 1.9, CI 1.0-3.7, P=0.06), previous
or current ART at the time of admission (OR= 3.5, CI
1.2-10.6, P=0.03), and CD4+ T lymphocyte count <50
(OR= 4.3, CI 1.5-12.6, P=0.01) were independently 
associated with mortality.
Table 1
Baseline charactristics of patients with cryptococcal meningitis admitted at Kenyatta National Hospital and 
Mbagathi District Hospital between August 2008 and March 2009
Variable Frequency n=76(%)
Age, median years (range) 35(20-53)
Sex
   Females 30(40)
   Males 46(60)
Time to discharge: median days (range) 22(5-68)
Time to death: median days (range) 10(3-74)
TB co-infection 25(33)
HIV-seropositive at admission 26(36)
ART, current or previous 19(25)
CD4+ T lymphocyte count in cells/mm3
Not measured 22(29)
   ≤25 19(25)
   25-99 24(31)
   100-249 9(12)
   ≥250 2(3)
Median(range) 31(1-468)
Viral load, median HIV-1 RNA copies/μl (range) 605,000(207-6,000,000)
CSF protein/glucose levels
   Not measured 39(51)
   High CSF protein levels 24(32)
   Low CSF glucose levels 33(42)
Complete blood count
   Not done 29(38)
   Low hemoglobin levels 15(20)
   Low white blood cells count 13(17)
Baseline creatinine and electrolytes
   Not measured 41(54)
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   Measured 35(46)
   Measured more than once 25(33)
   Creatinine, median μmol/L (range) 91(42-153)
Antifungal therapy
   None 5(7)
   AmB and FLC 39(51)
   AmB alone 23(30)
   FLC alone 9(12)
   ART initiated 8(11)
Analgesics
   None 16(21)
   Paracetamol 40(53)
   Tramadol 13(17)
   Brufen 14(18)
   Diclofenac 13(17)
   Antibiotics
   None 4(5)
   Co-trimoxazole 54(72)
   Benzylpenicillin 48(63)
   Ceftriaxone 32(42)
   Chloramphenicol 32(42)
Table 2
In-hospital mortality profile of HIV positive patients with CM in Kenya, August 2008- March 2009
Variable Alive  
n = 46 (%)
Dead  
n = 30 (%)
P-value
Hospital
Kenyatta National Hospital 16 (40) 14 (39) 0.58
Mbagathi District Hospital 24 (60) 16 (61)
Outcome after two weeks of admission 54 (71) 22 (29) 0.07
Age, median years (range) 35.0 (20-46) 35.5 (25-53) 1.00
Sex
Females 18 (39) 12 (40) 1.00
Males 28 (61) 18 (60)
Antifungal therapy
None 1 (2) 4 (13) 0.08
AmB and FLC 27 (59) 12 (40) 0.26
AmB alone 13 (28) 10 (34) 0.80
FLC alone 5 (11) 4 (13) 0.73
ART
Current or previous 14 (30) 5 (17) 0.28
Initiated 8 (17) 0 (0) 0.007
TB co-infection 10 (22) 15 (50) 0.04
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Co-morbidity present 15 (33) 22 (73) 0.01







CD4+ T lymphocyte count, median cells/
mm3 (range)
49 (1-468) 14 (3-214) <0.001
Antibiotics administered
Any 44 (96) 27 (90) 0.30
None 1 (2) 3 (10) 0.32
Co-trimoxazole 36 (78) 18 (60) 0.35
Benzylpenicillin 32 (70) 16 (53) 0.38
Ceftriaxone 21 (46) 11 (37) 0.55
Chloramphenicol 18 (39) 14 (47) 0.62
Metronidazole 2 (4) 3 (10) 0.38
Baseline creatinine and electrolytes
Not measured 25 (54) 16 (53) 0.95
Measured 21 (46) 14 (47) 0.84
At least six times 8 (17) 0 (0) 0.02
At least four times 18 (39) 2 (7) 0.002
At least twice 20 (43) 5 (17) 0.02
Once 1 (2) 9 (30) <0.001
Values in bold are statistically significant at p<0.05
Chi square and student t-test were used for categorical and continuous variables, respectively.
Co-morbidity include ; TB , hepatitis B, brain abscess, 
Kaposi’s sarcoma, gastroenteritis, hypertension, 
diabetes, cerebral atrophy, subarachnoid hemorrhage, 
epilepsy, ulcer, psychosis, pellagra, respiratory tract 
infection, and oral candidiasis.
DISCUSSION
This study reveals that there is high mortality 
associated with CM in patients with HIV/AIDS in 
public hospitals in Kenya and discusses some aspects
of CM management that can be improved. The study
identified predictors of mortality among patients with
CM and highlighted the need to address the existing
gaps in the management of this disease in Kenya. 
 CM associated mortality in our inpatient 
population, both at two weeks (29%) and overall 
(39.5%) is consistent with previously published 
studies from Africa (9,10). We found that the majority
of the deceased patients (73%) died during the first
two weeks of admission. This may be attributed to late
presentation of patients as evidenced by low CD4+ T
lymphocyte counts and high viral loads at admission.
As expected, patients with CD4+ T lymphocyte 
count < 50 fared worse than their counterparts. Our 
study also revealed that patients who had previously 
received or were currently receiving ART at the time
of admission were four times more likely to die. This
may be attributed to advanced HIV/AIDS stage at 
presentation to hospital. A recent cost-effectiveness 
study supported routine cryptococcal antigen 
(CRAG) screening for patients beginning ART since 
detection is possible three weeks before CM clinical 
symptoms manifest (11). In limited resource settings, 
early screening and appropriate FLC prophylaxis 
could potentially ease the burden of CM in patients 
with AIDS. 
 Although the patients who completed AmB 
treatment fared well, it should be noted that 20 
patients who were started on AmB, either alone or in 
combination with FLC, died. Based on the univariate 
analysis, we suspect that the inadequate monitoring 
of creatinine and electrolyte levels may also have 
contributed to these deaths. Ideally, AmB should 
be stopped if significant nephrotoxicity develops 
(7-9). All the six patients who were not tested for 
renal function after AmB treatment was started died. 
Although this may be due to patients dying before they 
could be monitored properly, we found a protective 
effect from being tested even once after treatment. 
Specifically, of the 24 patients who were treated 
with AmB and had creatinine and electrolyte levels 
monitored at least once after treatment initiation, 
only five died. Although AmB is the most effective 
antifungal available for patients with CM, our results 
show the benefit of treatment is blunted without 
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proper assessment of renal function. Even in areas 
of limited resources, adequate monitoring should be 
feasible.
 Since patients at MDH must wait for their families
to procure AmB, which can be costly (USD 200), FLC
was sometimes given as the first-line of treatment. This is
unfortunate since AmB is known to clear cryptococcal
infections more rapidly than FLC (12). While mortality
was not significantly associated with any of the three
combinations of antifungal therapy (AmB, FLC, AmB
and FLC) in our study, the unavailability of AmB may
be negatively impacting the health of patients with
CM. Even though AmB is given as soon as it becomes
available, at which time FLC is stopped, this delay
may be as long as one week. Consideration should be
given to increasing the availability of AmB in public
hospitals (13).
 Few studies on CM have evaluated the impact 
of co-morbidity, which is often present in immuno-
compromised patients and likely contributes to 
mortality. We found that the survival for the patients
co-infected with TB was only 40%, significantly 
lower in comparison with the proportion of patients 
without TB. Of note, rifampicin, a mainstay of anti-
TB therapy, was previously shown to hasten the 
elimination of FLC from the body (14,15). The clinical 
impact of this interaction is still unknown. To our 
knowledge, no clinical trial has included patients 
with CM and TB as a separate treatment group. 
Further studies should determine the prevalence of 
concomitant TB and compare the clinical presentation, 
treatment, and outcome of these patients to those 
solely infected with CM. As evident from the 
data, several antibiotics, including co-trimoxazole, 
chloramphenicol, benzylpenicillin, and ceftriaxone 
are widely used in the management of CM in the 
two hospitals but the association of these drugs with 
clinical outcome is unknown.
 We found that initiation of ART during the 
induction phase of antifungal treatment was 
associated with survival. Currently available data do 
not provide a consensus on when to initiate ART in 
patients who have received AmB treatment (16). With 
the increasing access to ART in sub-Saharan Africa 
and other developing areas, research efforts should 
focus on making recommendations for the timing 
of ART initiation in patients with CM. In particular, 
there is a concern that CM relapse, which often occurs 
as a result of immune reconstitution inflammatory 
syndrome (IRIS) secondary to starting ART after AmB 
treatment, may lead to increased mortality (17,18). We 
were unable to follow up patients for development 
of cryptococcal IRIS, normally seen after 30 days of 
ART initiation (17).
 There are several limitations to this study. First, 
mortality or survival was our only endpoint. CSF 
culture status after two weeks of treatment would 
have been a useful measure of success of treatment, but 
the standard of care at these hospitals did not include 
regularly scheduled follow-up lumbar punctures. 
Although therapeutic lumbar punctures are known 
to have been carried out, patient records do not 
reflect such management for intracranial pressure. 
Also, we could not ascertain the cause of death 
of the patients, and therefore, other AIDS-related 
complications may have contributed to mortality, 
especially in individuals who died several weeks 
after CM diagnosis. Finally, the study data were 
exclusively collected from inpatient files and we 
could not investigate long-term survival or factors 
associated with relapse.
In conclusion, this study found that the in-hospital
mortality is high. Although the poor prognosis
may be partly explained by late stage of disease at
presentation, mortality can be reduced by adjusting
modifiable factors. For instance, all patients receiving
AmB must be regularly monitored to detect possible
nephrotoxicity, at which point treatment may be
changed. Also, CRAG testing of patients receiving
ART may lead to early, improved CM management.
Long-term goals for CM management should be to
determine optimal treatment regiments for patients
with comorbidities such as TB. Improving the survival
of these patients alone would largely improve
outcomes among patients with CM. Resistance of C.
neoformans to FLC, which has been reported in Kenya,
and its effect on clinical outcomes, will require further
studies (18). Finally, there is a pressing need to improve
access to the most effective antifungal drugs in Kenya.
The problem of AmB availability in resource-limited
settings cannot be overemphasised.
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